Oligopin® contains French Maritime Pine Bark Extract

Placebo is a mixture of different inert compounds

Metabolic Syndrome

French Maritime Pine Bark Extract - 100mg/day

Oligopin®

Placebo

KGK Science Inc.

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Change in fasting blood sugar from baseline to day 84 between Oligopin® and placebo.

Change in fasting insulin between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting glucose between Oligopin® and placebo baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting LDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting oxLDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting HDL between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in fasting total cholesterol between Oligopin® and placebo baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in postprandial glucose between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in BMI between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in waist circumference between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in systolic and diastolic blood pressure between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in heart rate between Oligopin® and placebo from baseline to day 42, baseline to day 84, and from day 42 to day 84

Change in ALT between Oligopin® and placebo pre-baseline and day 84.

Change in AST between Oligopin® and placebo pre-baseline and day 84.

Change in total bilirubin between Oligopin® and placebo pre-baseline and day 84.

Change in creatinine between Oligopin® and placebo pre-baseline and day 84.

Change in sodium ion between Oligopin® and placebo pre-baseline and day 84.

Change in potassium ion between Oligopin® and placebo pre-baseline and day 84.

Change in chloride ion between Oligopin® and placebo pre-baseline and day 84.

Change in eGFR between Oligopin® and placebo pre-baseline and day 84.

Change in WBC count between Oligopin® and placebo pre-baseline and day 84.

Change in neutrophil count between Oligopin® and placebo pre-baseline and day 84.

Change in lymphocyte count between Oligopin® and placebo pre-baseline and day 84.

Change in monocyte count between Oligopin® and placebo pre-baseline and day 84.

Change in eosinophil count between Oligopin® and placebo pre-baseline and day 84.

Change in basophil count between Oligopin® and placebo pre-baseline and day 84.

Change in RBC count between Oligopin® and placebo pre-baseline and day 84.

Change in hemoglobin level between Oligopin® and placebo pre-baseline and day 84.

Change in hematocrit level between Oligopin® and placebo pre-baseline and day 84.

Change in platelet count between Oligopin® and placebo pre-baseline and day 84.

Change in MCV level between Oligopin® and placebo pre-baseline and day 84.

Change in MCH level between Oligopin® and placebo pre-baseline and day 84.

Change in MCHC level between Oligopin® and placebo pre-baseline and day 84.

Change in MPV level between Oligopin® and placebo pre-baseline and day 84.

Change in RDW level between Oligopin® and placebo pre-baseline and day 84.

Les Derives Resiniques et Terpeniques

Intervention group that will intake 100 mg of Oligopin® for 6 weeks

Placebo group that will intake 250 mg of Maltodextrin

Skin Aging

Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.

Oligopin

Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate

Technological Centre of Nutrition and Health. Eurecat_Reus.

Centro Tecnológico de Nutrición y Salud (Eurecat-Reus)

Effect of Oligopin® on Skin Ageing

Effect of a French Maritim Pine Bark Extract Oligopin® on Skin Ageing. Double Blind, Parallel, Randomized, Placebo Controled Intervention Trial

Skin elasticity measured by using a Cutometer® MPA 580

Skin wrinkles measured using DermoPrime System

Skin hydratation measured using DermoPrime System

Skin spots measured using DermoPrime System

Subepidermal low-echogenic band measured by ultrasound echogenicity quantitative approach

Serum levels of Human Procollagen I N-Terminal Propeptide, Human Procollagen I C-Terminal Propeptide, Human C-Telopeptide of Type I Collagen, Fibronectin, Elastin, Hyaluronic acid, MMP-1, TIMP-1. These biomarkers will be measured using humans ELISA kits.

Expression levels in PBMCs by quantitative polymerase chain reaction (qPCR) of the following genes: Collagen type I alpha 1 chain gene (Col1a1), Collagen type I alpha 2 chain gene (Col1a2), Mmp-2, Timp-1.

Oligopin® blood metabolites will be measured by liquid chromatography quadruple Time-of-Flight (LC-qTOF). It will be analyzed the correlations between specific Oligopin® metabolites and its effects on skin, as well as on serum and PBMCs biomarkers.

Transcriptomics in PBMCs analyzed using microarrays Agilent technologies

Non-targeted metabolomics of aqueous and lipid fraction of serum samples measured using proton nuclear magnetic resonance

Postprandial Oligopin® blood metabolites characterization after 700 mg Oligopin® consumption and measured by LC-qTOF. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of total collagen concentration in cells and cultured media. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of secreted collagen type I. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of secreted collagen type III. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of mRNA levels of pyruvate target genes in cells measuring expression levels of elastin, Col1a1, Col1a2, Col3a1, Mmp-1 and Timp-1 genes. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of MMP-1 activity in culture medium. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of TIMP-1 levels in culture medium. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of inhibitory effect on MMP-1. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of inhibitory effect on MMP-2. The measurements will be done at 0 hours, 2 hours and 6 hours.

The capacity of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of inhibitory effect on MMP-9. The measurements will be done at 0 hours, 2 hours and 6 hours.

The effect of Oligopin® blood metabolites to modulate collagen dynamics using human fibroblast cell line treated with Oligopin® blood metabolites and determination of collagen fibers cross-linking effect. The measurements will be done at 0 hours, 2 hours and 6 hours.

procyanidin d 1/bor biljni rod

A Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome

Effect of Oligopin® on Skin Ageing

Najkompletnija baza ljekovitog bilja potpomognuta znanošću